New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
08:59 EDTVCYTVeracyte shares well positioned in 2014, says Leerink
Leerink believes Veracyte shares are well positioned in 2014 with potential catalysts from additional positive coverage decisions and the launch of the Afirma malignant test. The firm raised its price target for shares to $21 from $17 and maintains an Outperform rating on the name.
News For VCYT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 14, 2014
10:00 EDTVCYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:02 EDTVCYTVeracyte downgraded to Neutral from Buy at Janney Capital
November 13, 2014
16:12 EDTVCYTVeracyte sees FY14 revenue $38M, consensus $38.48M
Subscribe for More Information
16:11 EDTVCYTVeracyte reports Q3 EPS (37c), consensus (35c)
Subscribe for More Information
November 10, 2014
10:04 EDTVCYTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:17 EDTVCYTVeracyte initiated with an Equal Weight at Morgan Stanley
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use